Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460062 | 0.88 | SLC16A3 (0.46) | MRGPRX4NR4A2MAOAMAOBPTGDR2 | |
| SCHEMBL23460017 | 0.87 | MAOB (0.43) | DHODHSLC6A4MAOAMAOBPTGDR2 | |
| SCHEMBL23460837 | 0.87 | TRPM8 (0.47) | MRGPRX4PTGER4TRPM8TRPV1RXRA | |
| SCHEMBL38147126 | 0.87 | TRPM8 (0.47) | MRGPRX4PTGER4TRPM8TRPV1RXRA | |
| SCHEMBL23460002 | 0.86 | CXCR2 (0.50) | SLC6A4MRGPRX4MAOBRXRARXRB | |
| SCHEMBL25548898 | 0.84 | DHODH (0.41) | DHODHSLC6A4MRGPRX4MAOAMAOB | |
| SCHEMBL23461794 | 0.83 | DHODH (0.39) | DHODHSLC6A4MRGPRX4MAOAMAOB | |
| SCHEMBL23461796 | 0.83 | DHODH (0.39) | DHODHSLC6A4MRGPRX4MAOAMAOB | |
| SCHEMBL23461810 | 0.83 | DHODH (0.39) | DHODHSLC6A4MRGPRX4MAOAMAOB | |
| SCHEMBL23461824 | 0.82 | PTGDR2 (0.47) | DHODHSLC6A4MRGPRX4NR4A2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113806-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113808-A1 | CFTR-MODULATING ARYLAMIDES | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | DHODH 1799/4885SLC6A4 816/4885MRGPRX4 1064/4885 |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | DHODH 1523/4885SLC6A4 1384/4885MRGPRX4 886/4885 |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | DHODH 1523/4885SLC6A4 1384/4885MRGPRX4 886/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | DHODH 4151/4885SLC6A4 1208/4885MRGPRX4 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.